<DOC>
<DOCNO>EP-0629403</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Antibiotic combination
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31185	A61K3118	A61P3300	A61K31505	A61P3100	A61P3100	A61K31506	A61K31506	A61K31505	A61K3153	A61K31185	A61K3153	A61K3118	A61P3302	A61P3104	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61K	A61P	A61P	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P33	A61K31	A61P31	A61P31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P33	A61P31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Pharmaceutical products containing epiroprim and dapsone can be used to treat infections with mycobacteria, actinomyces and toxoplasmosis pathogens.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KOMPIS IVAN
</INVENTOR-NAME>
<INVENTOR-NAME>
THEN RUDOLF
</INVENTOR-NAME>
<INVENTOR-NAME>
KOMPIS, IVAN
</INVENTOR-NAME>
<INVENTOR-NAME>
THEN, RUDOLF
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Pharmaceutical preparations containing epiroprim and
dapsone as well as usual pharmaceutical carriers.
Preparations according to claim 1 containing epiroprim
and dapsone in the ratio of 1:100 to 100:1 parts by weight.
Preparations according to claim 1 containing epiroprim
and dapsone in the ratio of 1:1 to 1:5 parts by weight.
The use of epiroprim and dapsone for the production of
pharmaceutical preparations for the treatment of infections with

mycobacteria, Actinomycetes, especially Nocardia sp., and
toxoplasmosis pathogens.
</CLAIMS>
</TEXT>
</DOC>
